-+ 0.00%
-+ 0.00%
-+ 0.00%

U.S. FDA APPROVES UPDATE TO THE LABEL FOR WINREVAIR™ (SOTATERCEPT-CSRK) TO INCLUDE DATA FROM THE PHASE 3 HYPERION TRIAL EVALUATING ADULTS RECENTLY DIAGNOSED WITH PULMONARY ARTERIAL HYPERTENSION (PAH, WHO* GROUP 1 PULMONARY HYPERTENSION)

Reuters·09/22/2026 10:45:00

Please log in to view news